Sunil Healthcare Ltd Valuation Shifts Signal Improved Price Attractiveness Amid Mixed Returns

Valuation Metrics Signal Improved Price Attractiveness

Sunil Healthcare’s P/E ratio currently stands at 23.66, a figure that positions it attractively within the Pharmaceuticals & Biotechnology sector. This is a marked improvement from previous assessments that rated the stock as very attractive, reflecting a modest re-rating in the market. The company’s P/BV ratio is exactly 1.00, indicating that the stock is trading at book value, which is often considered a fair valuation benchmark for asset-heavy pharmaceutical firms.

Other valuation multiples such as EV to EBIT (17.22) and EV to EBITDA (9.02) further reinforce the stock’s attractive pricing relative to earnings before interest, taxes, depreciation, and amortisation. The PEG ratio, a critical measure of valuation relative to earnings growth, is exceptionally low at 0.09, suggesting that the stock is undervalued when factoring in its growth prospects.

However, return metrics remain subdued, with the latest return on capital employed (ROCE) at 5.00% and return on equity (ROE) at 2.55%, indicating modest profitability and efficiency in capital utilisation. These figures are below sector averages, which may temper enthusiasm despite the attractive valuation.

Comparative Analysis with Peers

When benchmarked against key peers in the Pharmaceuticals & Biotechnology sector, Sunil Healthcare’s valuation stands out as relatively attractive. For instance, Bliss GVS Pharma trades at a P/E of 20.33 but carries a higher EV to EBITDA multiple of 14.93 and a PEG ratio of 0.84, reflecting a fair valuation but less compelling growth value than Sunil Healthcare.

Conversely, companies such as Shukra Pharma and NGL Fine Chem are classified as very expensive, with P/E ratios of 62.08 and 40.25 respectively, and EV to EBITDA multiples soaring above 25. These valuations suggest that Sunil Healthcare offers a more reasonable entry point for investors seeking exposure to the pharmaceutical sector without paying a premium for growth or market positioning.

Interestingly, TTK Healthcare, another attractive valuation stock, trades at a lower P/E of 18.29 but has a significantly higher EV to EBITDA of 26.05 and an elevated PEG ratio of 7.78, indicating that Sunil Healthcare’s valuation is more balanced when considering both earnings and growth potential.

Stock Price and Market Performance Overview

Sunil Healthcare’s current market price is ₹66.00, showing a slight increase of 0.99% from the previous close of ₹65.35. The stock has traded within a range of ₹66.00 to ₹70.00 today, with a 52-week high of ₹88.70 and a low of ₹60.55. This range indicates some volatility but also a potential for upside given the proximity to the lower end of its annual trading band.

Examining the stock’s returns relative to the Sensex reveals a mixed picture. Over the past week, Sunil Healthcare has underperformed, declining by 4.35% compared to the Sensex’s 1.84% drop. However, over the last month, the stock has outperformed with a 3.11% gain against the Sensex’s 0.70% loss. Year-to-date, the stock has declined 9.03%, more than double the Sensex’s 4.62% fall, reflecting sector-specific headwinds or company-specific challenges.

Longer-term returns show a more positive trend, with a 5-year return of 148.59%, significantly outperforming the Sensex’s 65.55% over the same period. This suggests that despite recent volatility, Sunil Healthcare has delivered substantial value to investors over the medium term. However, the 10-year return is negative at -24.91%, contrasting sharply with the Sensex’s robust 251.07% gain, highlighting periods of underperformance and cyclical challenges.

Mojo Score and Rating Update

Sunil Healthcare’s MarketsMOJO score currently stands at 32.0, with a Mojo Grade of Sell, upgraded from a previous Strong Sell rating on 25 February 2026. This upgrade reflects the improved valuation parameters and a slightly more optimistic outlook on the stock’s near-term prospects. The company holds a Market Cap Grade of 4, indicating a mid-sized market capitalisation within its sector.

While the rating remains cautious, the upgrade signals that the stock’s risk-reward profile has improved, primarily due to its more attractive valuation metrics and potential for earnings recovery. Investors should weigh these factors against the company’s modest profitability and recent underperformance relative to broader market indices.

Investment Considerations and Outlook

Sunil Healthcare’s improved valuation metrics offer a compelling entry point for investors seeking exposure to the Pharmaceuticals & Biotechnology sector at a reasonable price. The P/E and P/BV ratios suggest that the stock is fairly valued relative to its book and earnings, while the low PEG ratio indicates undervaluation relative to growth potential.

However, the company’s low ROCE and ROE figures highlight ongoing challenges in generating strong returns on capital, which may limit upside in the absence of operational improvements. Additionally, the stock’s recent underperformance relative to the Sensex and sector peers warrants caution.

Investors should also consider the broader sector context, where several peers trade at significantly higher valuations, reflecting expectations of stronger growth or market positioning. Sunil Healthcare’s attractive valuation may appeal to value-oriented investors, but growth-focused investors might prefer peers with higher earnings momentum despite elevated multiples.

Conclusion: Valuation Improvement Offers Opportunity Amid Caution

Sunil Healthcare Ltd’s shift from very attractive to attractive valuation status marks a positive development for investors monitoring the stock. The company’s current P/E of 23.66 and P/BV of 1.00 provide a reasonable valuation base compared to its peers, many of whom trade at expensive multiples. The low PEG ratio further underscores the potential undervaluation relative to growth prospects.

Nevertheless, the company’s modest profitability ratios and mixed recent market performance suggest that investors should approach with measured optimism. The upgrade in Mojo Grade from Strong Sell to Sell reflects this balanced view, signalling improved but still cautious sentiment.

For investors seeking value within the Pharmaceuticals & Biotechnology sector, Sunil Healthcare presents an intriguing proposition, particularly given its attractive valuation metrics and long-term return history. However, those prioritising growth or stronger capital returns may find more compelling opportunities among its higher-rated peers.

Limited Period Only. Start at Rs. 9,999 - Get MojoOne for 1 Year + 3 Months FREE (60% Off) Get 71% Off →